SAM #W911SR-26-PLATFORM

RFI for Formulation-Agnostic Autoinjector Platform Development

The Department of Defense, Department of the Army, Army Contracting Command at Aberdeen Proving Ground (ACC-APG), is seeking information and design concepts for a next-generation autoinjector platform: - Government Buyer: - Department of Defense, Department of the Army, Army Contracting Command (ACC-APG) - Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND) - Joint Project Manager for CBRN Medical (JPM CBRN Medical) - OEMs and Vendors: - No specific OEMs or vendors are named in the request - Products/Services Requested: - Formulation-agnostic autoinjector platform - Must be modular, ruggedized, and highly reliable - Capable of delivering: - Single-chamber liquid formulations - Dual-chamber liquid-liquid formulations - Dual-chamber solid-liquid (reconstitution) formulations - Delivery volume range: 0.4 mL to 5.0 mL - Must accommodate a range of viscosities - Initial compatibility with: Atropine, Pralidoxime Chloride (2-PAM), Midazolam, Naloxone - Unique or Notable Requirements: - FDA-validated reliability of 99.999% over the product lifecycle - Ruggedization to MIL-STD-810H standards - Capable of intramuscular delivery through protective gear - Designs should have dual-use commercial market potential beyond military procurement

Description

The Department of War (DoW), Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), Joint Project Manager for CBRN Medical (JPM CBRN Medical) is seeking information, design concepts, and capabilities for a Formulation-Agnostic Autoinjector Platform.

The goal of this initiative is to identify or develop a modular, ruggedized, and highly reliable autoinjector device capable of delivering single-chamber liquid, dual-chamber liquid-liquid, or dual-chamber solid-liquid (reconstitution) formulations.

Key Technical Parameters & Scope:

Reliability: Must design toward or meet an FDA-validated reliability threshold of 99.999% over the product lifecycle. Flexibility: Capable of delivering volumes ranging from 0.4 mL to 2.0 mL (Threshold) up to 5.0 mL (Objective) across varying fluid viscosities without design modifications to the primary assembly line. Ruggedization: Capable of meeting or being ruggedized to MIL-STD-810H standards, ensuring intramuscular (IM) delivery through Mission Oriented Protective Posture (MOPP) gear and Army Combat Uniforms (ACU). Target Compounds: Initial candidates include Atropine, Pralidoxime Chloride (2-PAM), Midazolam, and Naloxone. Commercialization: The Government seeks platform designs with clear dual-use pathways for sustainable commercial market viability beyond military procurement.

This RFI is for market research and planning purposes only. It does not constitute a solicitation, nor does it restrict the Government's ultimate acquisition strategy.

View original listing